|Study Description:||The goal of this Phase 1 clinical research study is to learn the highest |
tolerable dose of the combination of the drugs BKM120 and Lynparza™ (olaparib)
or BYL719 and olaparib that can be given to patients with recurrent breast or
ovarian cancer. The safety of these drugs will also be studied.
BKM120, BYL719, and olaparib are both designed to block the growth and division
of cancer cells, which may cause the cells to die.